Quarterly report [Sections 13 or 15(d)]

Fair Value of Financial Instruments - Narrative (Details)

v3.26.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Feb. 25, 2025
Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]          
Warrants outstanding (in shares) 2,633,195   2,633,195 5,098,978  
Changes in fair value $ 319        
Common Stock          
Subsidiary, Sale of Stock [Line Items]          
Common issued for warrants exercised (in shares)   9,499,138      
Private Warrants          
Subsidiary, Sale of Stock [Line Items]          
Warrants outstanding (in shares) 2,633,195       7,732,168
Number of warrants to purchase common stock (in shares)         1
Fair value (in dollars per share)         $ 11.50
Changes in fair value $ 319 $ (13,600)      
Fair value, liability, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income   Other Nonoperating Income (Expense)      
Class of warrants exercised (in shares)   4,631,799      
Warrants exercised (in shares)   467,174      
Proceeds from warrant exercises   $ 5,400      
Private Warrants | Common Stock          
Subsidiary, Sale of Stock [Line Items]          
Common issued for warrants exercised (in shares)   2,293,739      
Warrants exercised (in shares)   467,174